Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
Home / BiomarkerLive / Advisory Committee

Advisory Committee

Patricia Friend
Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC
Associate Professor and Program Director
Marcella Niehoff School of Nursing, Loyola University Chicago
Chicago, IL

Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC, has advanced certification in oncology nursing and is board-certified in advanced genetics nursing. Her areas of expertise are in oncology and genomics, educational preparation of advanced practice nurses, online education, and interprofessional education and practice. Her doctoral dissertation work was supported by the American Cancer Society (doctoral scholarship) and a pre-doctoral fellowship (F31) from the National Cancer Institute. Her doctoral research, examining the interactions between stress and immune responses in women undergoing diagnostic breast biopsy, was funded by the National Cancer Institute, the Oncology Nursing Foundation, and the Chicago Chapter of the Oncology Nursing Society. Additionally, Dr. Friend has experience with educational training grants and currently leads a team of faculty supported by the NCI-sponsored Interprofessional Education Exchange (iPEX) Project, that is developing interprofessional education in palliative care.

Dr. Friend’s main area of clinical scholarship and research interest is in the area of genetics/genomics. She serves on the Genomics Advisory Board for the Oncology Nursing Society and is interested in improving genomic literacy of healthcare educators, students, and clinicians.

Jennifer Godden
Jennifer Godden, PharmD, BCOP
Co-Director, Oncology Precision Medicine
Advocate Aurora Health Care
Milwaukee, WI
Jennifer Godden, PharmD, BCOP, is the co-director of oncology precision medicine at Advocate Aurora Health Care in Milwaukee, Wisconsin. Dr. Godden received her Doctor of Pharmacy degree from the University of Iowa in 2007, graduating with high distinction. Following graduation, she completed a PGY-1 pharmacy practice residency with Aurora Health Care (AHC), having worked there for an additional two years as an inpatient clinical pharmacist before accepting an offer to become the first PGY-2 oncology pharmacy specialty resident.

After her second residency she continued to work for AHC as an oncology clinical coordinator for five years before transitioning to her current position. Dr. Godden is board certified as an oncology pharmacist by the American College of Clinical Pharmacy, and is a member of the Hematology/Oncology Pharmacy Association and the Pharmacy Society of Wisconsin.
Edward Kim
Edward Kim, MD
Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute, Atrium Health
Charlotte, NC
Edward S. Kim, MD, is chair of solid tumor oncology and investigational therapeutics, medical director of the clinical trials office, and the Donald S. Kim distinguished chair for cancer research at the Levine Cancer Institute, Atrium Health in Charlotte, North Carolina. 

Dr. Kim specializes in cancer biomarkers and novel targeted agents in treatment and prevention settings, including expertise in lung, head, and neck cancers. He chaired the Department of Defense Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer, and currently oversees the solid tumor faculty and research development at Levine Cancer Institute.

Dr. Kim was previously at the University of Texas MD Anderson Cancer Center in Houston where he was a tenured associate professor of medicine, chief of the section of head and neck medical oncology, and director of clinical research operations in the Department of Thoracic/Head and Neck Medical Oncology.

He received his medical degrees from the Honors Program in Medical Education (HPME) at Northwestern University, and completed his residency at Baylor College of Medicine, and his fellowship in medical oncology at the University of Texas MD Anderson Cancer Center.
Annette Kim
Annette Kim, MD, PhD
Associate Director, Center for Advanced Molecular Diagnostics
Associate Professor of Pathology, Harvard Medical School
Hematopathologist and Molecular Pathologist, Brigham and Women's Hospital
Boston, MA
Annette S. Kim, MD, PhD, is an associate professor of pathology at Harvard Medical School and a practicing hematopathologist and molecular pathologist at Brigham and Women's Hospital. She has prior training in synthetic organic chemistry as well as structural biology and spent several years in the pharmaceutical industry prior to her return to academia. Since returning to clinical practice, Dr. Kim has practiced diagnostic hematopathology and molecular pathology, serving as associate director of the Center for Advanced Molecular Diagnostics, a role in which she has directed assay validation and quality assurance.

Dr. Kim's research program has focused on the study of myeloid neoplasms, mutational patterns in hematopoietic neoplasms, and test utilization. Her research program has identified diagnostic and prognostic small non-coding RNAs in MDS via next generation sequencing and defined the role of hypermethylation in the regulation of miRNAs in MDS. She has studied the effects of potential therapeutic compounds on cellular function in miRNA-based models of the MDS and in primary clinical samples using single cell phenotyping by mass cytometry with correlation to the mutational profiles of these samples.

Dr. Kim has been an active member of the Association of Molecular Pathology, serving as chair of several committees and a member of the Executive Committee, Strategic Opportunities Committee, and board. She also serves on the College of American Pathologists Molecular Oncology Committee. Through these societies she has published key papers on myeloid mutational patterns and performance of FDA companion diagnostics and laboratory developed assays, including performance of next generation sequencing assays.
Scott VandenBerg
Scott VandenBerg, MD, PhD
Director, Tissue Core Facility
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Scott VandenBerg, MD, PhD, is the director of the Tissue Core Facility at UCSF Helen Diller Family Comprehensive Cancer Center, with extensive experience developing tissue-based biomarker techniques and directing biorepositories for the optimal acquisition, archiving, annotation, and custodianship of human tissue for cancer research. Dr. VandenBerg’s technical expertise in molecular morphology include immunohistochemistry/immunofluorescence and molecular in situ analyses.

Since 2008, a major emphasis of his technical research core activities has been to develop more quantitative detection of biomarkers of activated signaling pathways in a wide spectrum of human disease, focusing on cancer. His translational research focuses on the application of multiple proteomic, epigenetic, and genetic techniques for the molecular morphologic analysis of biomarkers in CNS tumor sections. The technologies include processing techniques for tissue to preserve analyte quality for RNA, DNA, and proteomics with optimal histologic quality and multiple detection modalities on tissue sections for biomarker multiplexing in heterogeneous tumors, including the genomic and proteomic characterization of prognostic markers in CNS tumors.

Dr. VandenBerg directed the establishment of a tissue technology laboratory to optimize the use of quantitative immunofluorescence detection techniques for combined IF/ISH analyses and for the multiplex analysis of inter-related signaling pathways in human tissue, focusing on cancer. Prior to joining UCSF, Dr. VandenBerg was director of the UCSD Moores Comprehensive Center Biorepository, Histopathology, and Tissue Technology Shared Resource.

Our Partners



Our Supporters

logo-abbvie-200x80 This project is supported by AbbVie, Lilly Oncology, and Merck & Co., Inc. BMS-330x80 Phase one of this project was supported by Bristol Myers Squibb.